In March, GSK Consumer Healthcare launched Children’s Flonase, which blocks six allergic substances, reduces inflammation and relieves allergy symptoms caused by pollen, mold spores, dust mites and pet dander.
GSK Consumer Healthcare’s Flonase allergy remedy was the single greatest generator of incremental dollars for the 52 weeks ended May 15 across total U.S. multi-outlets, according to IRI data, with $345.2 million in sales on 209.9% growth.
With medication nonadherence estimated to cost the U.S. healthcare system anywhere between $100 billion and $300 billion dollars, pharmacy technology companies are looking to create tools that pharmacists can implement to help patients be more adherent.
As some companies prepare to market their biosimilars, others are still in development. At the end of 2015, the IMS Institute noted that there were five biosimilars in the pre-registration phase of development.
Total spending on products whose patents expired between 2012 and 2015 declined by $14.2 billion last year, according to IMS Health’s Institute for Health Care informatics. And 2016 could bring about further cost reductions.
As interest in telehealth options increases, so too does the diversification of the services offered through telehealth providers. Both patients and telehealth companies are looking at behavioral health as the next frontier in remote care.
PricewaterhouseCooper’s Health Research institute found that 60% of patients would be willing to use their mobile device for a physician visit. he increased interest in telehealth comes as Mordor Intelligence projects the industry will be worth more than $34 billion by 2020.
For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.